Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Pass Below 200 Day Moving Average – Time to Sell?

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.54 and traded as low as $0.3951. Elite Pharmaceuticals shares last traded at $0.3980, with a volume of 653,525 shares trading hands.

Elite Pharmaceuticals Trading Down 0.4%

The company has a quick ratio of 5.44, a current ratio of 7.34 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $416.95 million, a P/E ratio of 12.91 and a beta of 0.35. The firm’s 50-day simple moving average is $0.43 and its 200-day simple moving average is $0.54.

Elite Pharmaceuticals (OTCMKTS:ELTP) last posted its quarterly earnings data on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%. The firm had revenue of $31.59 million for the quarter.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.